SK Life Science, Inc. clinical trials

A subsidiary of SK Biopharmaceuticals

The registry lists 43 studies whose lead sponsor is SK Life Science, Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2026.

Studies

Recruiting first, then most recently updated. Showing 43 of 43. All SK Biopharmaceuticals studies →

• SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid TumorsRecruitingNCT07812805Phase 1

  Sponsor listed in the registry: SK Life Science, Inc.

• Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and AdultsRecruitingNCT05219617Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.

• Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) SeizuresCompletedNCT05067634Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.

• Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset EpilepsyActive, not recruitingNCT06453213Phase 4

  Sponsor listed in the registry: SK Life Science, Inc.

• Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC SeizuresCompletedNCT03678753Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.

• Cenobamate Open-Label Extension Study for YKP3089C025CompletedNCT03961568Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.

• Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POSCompletedNCT04557085Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.

• Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset SeizuresCompletedNCT04903314Phase 1

  Sponsor listed in the registry: SK Life Science, Inc.

• A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset SeizuresCompletedNCT01866111Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors PatientsTerminatedNCT05388435Phase 1/2

  Sponsor listed in the registry: SK Life Science, Inc.

• A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug UsersCompletedNCT03509285Phase 1

  Sponsor listed in the registry: SK Life Science, Inc.

• A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered OrallyCompletedNCT05572255Phase 1

  Sponsor listed in the registry: SK Life Science, Inc.

• Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug InteractionsCompletedNCT03234699Phase 1

  Sponsor listed in the registry: SK Life Science, Inc.

• Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and TabletCompletedNCT04690751Phase 1

  Sponsor listed in the registry: SK Life Science, Inc.

• Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset SeizuresCompletedNCT02535091Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.

• Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut SyndromeCompletedNCT04062981Phase 1

  Sponsor listed in the registry: SK Life Science, Inc.

• Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic ImpairmentCompletedNCT04791553Phase 1

  Sponsor listed in the registry: SK Life Science, Inc.

• Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy SubjectsCompletedNCT04505397Phase 1

  Sponsor listed in the registry: SK Life Science, Inc.

• Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut SyndromeCompletedNCT03731715Phase 1

  Sponsor listed in the registry: SK Life Science, Inc.

• Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset SeizuresCompletedNCT01397968Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• Cenobamate Expanded Access Program (EAP)Approved for marketingNCT04513860

  Sponsor listed in the registry: SK Life Science, Inc.

• Bioavailability and Food Effect Study of 3 Types of CarisbamateCompletedNCT04520360Phase 1

  Sponsor listed in the registry: SK Life Science, Inc.

• An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).CompletedNCT00492323Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).CompletedNCT00501202Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable SchizophreniaCompletedNCT02205099Phase 1/2

  Sponsor listed in the registry: SK Life Science, Inc.

• A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral NeuropathyCompletedNCT01521598Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic ConstipationCompletedNCT01989234Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional ConstipationCompletedNCT01523184Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• Efficacy of YKP3089 in Patients With Photosensitive EpilepsyCompletedNCT00616148Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset SeizuresCompletedNCT00744731Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.

• An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.CompletedNCT00991757Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.

• Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.TerminatedNCT00563459Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.

• An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With EpilepsyCompletedNCT00210522Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.CompletedNCT00740623Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.

• An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With EpilepsyCompletedNCT00210652Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential TremorCompletedNCT00524056Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in DiabeticsCompletedNCT00870454Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset SeizuresTerminatedNCT00697762Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.

• Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset SeizuresCompletedNCT00697918Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.

• Safety and Efficacy of 333369 in the Treatment of Partial EpilepsyCompletedNCT00228969Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• A Study of the Efficacy of RWJ-333369 in the Prevention of MigraineCompletedNCT00109083Phase 2

  Sponsor listed in the registry: SK Life Science, Inc.

• A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.CompletedNCT00425282Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.

• A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.CompletedNCT00433667Phase 3

  Sponsor listed in the registry: SK Life Science, Inc.